Nectar Lifesciences Limited (NLL) is known for manufacturing cephalosporin antibiotics and medicines. Its journey began as a small active pharmaceutical ingredients (API) producer and has now transformed into being one of the leading players in the anti-infective therapeutic area. Its major business revolves around the manufacturing of APIs, formulations, and empty hard gelatin capsules. With the support of 11 manufacturing facilities in Punjab and Himachal Pradesh, NLL is able to serve and save lives in more than 45 countries. As per Bio-Spectrum Asia Pacific in 2016, Nestar Lifesciences is among the top 40 forerunners in the biopharmaceutical industry in the Asia-Pacific region.
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 1739 8.1% | 1608 -3.4% | 1664 15.4% | 1443 -39.3% | 2375 -16.4% | 2839 48.5% | 1912 15.3% | 1658 -2.8% | 1706 0.8% | 1692 -0.9% | 1708 0.1% | 1707 16.8% | 1461 26.2% | 1158 28.5% | 901 3.7% | 869 - |
Net Operating Income (INR Cr) | 1684 10.53% | 1524 -8.70% | 1669 8.13% | 1543 -34.78% | 2366 -14.97% | 2783 48.32% | 1876 14.15% | 1644 -1.91% | 1676 1.95% | 1644 0.33% | 1638 0.74% | 1626 23.85% | 1313 23.64% | 1062 25.57% | 846 16.19% | 728 -1.08% |
Profit (INR Cr) | 5 - | -24 - | 25 - | -73 - | 32 -33.2% | 48 -8.9% | 52 -5.6% | 55 2.0% | 54 -18.1% | 66 6.7% | 62 -27.6% | 86 17.1% | 73 -29.7% | 104 12.9% | 92 74.2% | 53 - |
Assets (INR Cr) | 1713 -6.1% | 1826 -6.7% | 1956 -1.0% | 1976 2.6% | 1926 -5.2% | 2031 -0.5% | 2041 6.7% | 1913 -1.4% | 1940 1.9% | 1904 6.3% | 1791 2.3% | 1752 -4.4% | 1833 33.5% | 1373 12.4% | 1222 21.2% | 1008 - |
Net Worth (INR Cr) | 1069 0.4% | 1065 -2.1% | 1088 2.4% | 1062 -6.5% | 1136 2.8% | 1105 4.4% | 1059 5.2% | 1007 5.5% | 954 -0.4% | 958 3.3% | 927 6.9% | 868 10.6% | 784 8.8% | 721 16.2% | 621 104.6% | 303 6.8% |
Employee Cost (INR Cr) | 82 8.7% | 75 4.5% | 72 1.9% | 71 -9.7% | 78 2.2% | 77 2.5% | 75 -1.2% | 76 -3.6% | 78 33.0% | 59 22.9% | 48 5.1% | 46 3.9% | 44 30.0% | 34 16.7% | 29 11.0% | 26 - |
Interest Cost (INR Cr) | 87 | 79 | 79 | 112 | 126 | 148 | 115 | 117 | 123 | 126 | 138 | 115 | 115 | 74 | 60 | 50 |
Cash & Bank Balance (INR Cr) | 20 | 18 | 18 | 26 | 21 | 21 | 9 | 13 | 37 | 33 | 10 | 6 | 26 | 33 | 35 | 34 |
Total Debt (INR Cr) | 636 | 754 | 860 | 903 | 779 | 903 | 955 | 878 | 962 | 925 | 858 | 879 | 1043 | 648 | 601 | 704 |
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit As % Of Revenues | 0.3% | - | 1.5% | - | 1.3% | 1.7% | 2.7% | 3.3% | 3.2% | 3.9% | 3.6% | 5.0% | 5.0% | 9.0% | 10.2% | 6.1% |
Profit As % Of Assets | 0.3% | - | 1.3% | - | 1.7% | 2.3% | 2.6% | 2.9% | 2.8% | 3.5% | 3.5% | 4.9% | 4.0% | 7.6% | 7.6% | 5.3% |
Profit As % Of Networth | 0.5% | - | 2.3% | - | 2.8% | 4.3% | 4.9% | 5.5% | 5.7% | 6.9% | 6.7% | 9.9% | 9.3% | 14.5% | 14.9% | 17.5% |
Interest Cost to EBITDA % | 57.5% | 150.0% | 49.7% | 133.8% | 57.3% | 56.1% | 48.8% | 52.3% | 51.7% | 47.1% | 47.8% | 39.8% | 46.4% | 32.6% | 30.9% | 36.0% |
Debt to Equity Ratio | 0.59 | 0.71 | 0.79 | 0.85 | 0.69 | 0.82 | 0.90 | 0.87 | 1.01 | 0.97 | 0.93 | 1.01 | 1.33 | 0.90 | 0.97 | 2.32 |
RONW | 0.5% | - | 1.7% | - | 2.8% | 4.4% | 5.1% | 5.6% | 5.7% | 7.0% | 6.9% | 10.4% | 9.7% | 15.5% | 20.0% | 18.0% |
ROCE | 6.0% | -0.2% | 5.3% | 2.7% | 8.3% | 10.2% | 9.0% | 9.6% | 9.7% | 11.4% | 12.2% | 12.9% | 12.5% | 15.0% | 15.8% | 12.8% |